<DOC>
	<DOCNO>NCT01382407</DOCNO>
	<brief_summary>The hypothesis study patient suffer acne vulgaris adolescence great risk develop acneiform skin rash due cetuximab .</brief_summary>
	<brief_title>Does Acne Rash During Adolescence Predict Skin Reaction Cetuximab</brief_title>
	<detailed_description>The hypothesis study patient suffer acne vulgaris adolescence great risk develop acneiform skin rash due cetuximab</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age 18 year . Histology cytology proven KRASWT mCRC . Performance status ≤3 ( Eastern Cooperative Oncology Group [ ECOG ] classification ) Life expectancy 12 week . Written informed consent . In woman childbearing potential , appropriate contraceptive measure must use treatment cetuximab 6 month follow last dose cetuximab . Past systemic immune therapy disease cancer . Past immune target therapy cancer ( include bevacizumab ) . Presence acne acneiform rash prior start treatment cetuximab . Patients treatment plan cetuximab capecitabine combination . For female patient : patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>skin rash reaction</keyword>
	<keyword>ERBITUX® ( cetuximab )</keyword>
	<keyword>acne</keyword>
</DOC>